FUM has advanced transdermal technology which can be incorporated into formulations of well characterised drugs to improve performance and extend their uses. 2015 was expected to be a busy year for the company and three recent announcements show that management is delivering on these expectations. Clarity of the EU regulatory pathway for the pain portfolio products is an important milestone, and rapid recruitment in the pivotal MED2002 trial, both add to the de-risking of the prodcuts and enh
25 Nov 2015
Update following company announcements
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Update following company announcements
Futura Medical plc (FUM:LON) | 34.1 -0.2 (-1.7%) | Mkt Cap: 102.9m
- Published:
25 Nov 2015 -
Author:
Mark Brewer -
Pages:
4
FUM has advanced transdermal technology which can be incorporated into formulations of well characterised drugs to improve performance and extend their uses. 2015 was expected to be a busy year for the company and three recent announcements show that management is delivering on these expectations. Clarity of the EU regulatory pathway for the pain portfolio products is an important milestone, and rapid recruitment in the pivotal MED2002 trial, both add to the de-risking of the prodcuts and enh